drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Off-the-shelf allogeneic CAR T-cell therapy engineered to express a CAR targeting CD33 to induce antigen-specific T-cell activation and lysis of AML cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic off-the-shelf T cells are engineered to express a chimeric antigen receptor targeting CD33; upon binding CD33 on AML cells, the CAR activates T-cell signaling (CD3ΞΆ with costimulatory domains) to induce cytokine release and perforin/granzyme-mediated lysis of the malignant cells.
drug_name
CD33-specific universal CAR T cells
nct_id_drug_ref
NCT05995041